ADRB3 and bronchopulmonary dysplasia: Overall, these findings further support the potential use of drugs targeting β3-AR as a new, valuable pharmacological approach for treating preterm infants against the common adverse effects of supplemental oxygen therapy, such as bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, and periventricular leukomalacia.